Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 190 | 214 | 239 | 262 | 294 | 321 | 337 | 337 |
| Operating profit | $bn | 3.93 | 4.39 | ||||||
| Net profit | $bn | -3.40 | 1.54 | 1.70 | 1.75 | 1.51 | 1.55 | 3.48 | 3.48 |
| EPS reported | $ | 17.95 | 17.92 | ||||||
| Operating cashflow per share | $ | 24.80 | 25.10 | ||||||
| Capex per share | $ | 4.71 | 4.77 | ||||||
| FCF per share | $ | 20.09 | 20.34 | ||||||
| Free cash flow | $bn | 3.88 | 3.88 | ||||||
| Net debt | $bn | 6.39 | 6.39 | ||||||
| Book value equity | $bn | 3.68 | 3.68 | ||||||
| Book value per share | $ | 18.97 | 19.20 | ||||||
| Number of shares | m | 194.09 | 191.74 | ||||||
| DPS (TTM paid) | $ | 2.46 | 2.40 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 16.73 | 19.52 | ||||||
| P/B LTM | x | 15.76 | 18.14 | ||||||
| P/S LTM | x | 0.17 | 0.20 | ||||||
| P/FCF LTM | x | 14.95 | 17.20 | ||||||
| EV/EBITDA LTM | x | 10.53 | 11.88 | ||||||
| EV/Sales LTM | x | 0.19 | 0.22 | ||||||
| Earnings Yield LTM | % | 5.98% | 5.12% | ||||||
| FCF Yield | % | 6.69% | 5.81% | ||||||
| Quality | |||||||||
| ROE | % | 94.64% | 115.76% | ||||||
| ROIC | % | 12.05% | 13.46% | ||||||
| Operating margin | % | 1.16% | 1.30% | ||||||
| Gross margin | % | 4.11% | 3.95% | ||||||
| FCF/Sales | % | 1.15% | 1.15% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +125.50% | +125.50% | ||||||
| Sales Growth YoY | % | +5.00% | +5.00% | ||||||
| Net Income Growth YoY | % | +124.16% | +124.16% | ||||||
| FCF Growth | % | +21.00% | +21.00% | ||||||
| Operating Profit Growth | % | +7.74% | +7.74% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.82% | 0.69% | ||||||
| Dividend Growth | % | +9.33% | +9.09% | ||||||
| Payout Ratio | % | 13.69% | 13.71% | ||||||
| FCF/Debt | x | 0.34 | 0.34 | ||||||
| Net Debt/EBITDA | x | 1.04 | 1.04 | ||||||
| EBIT/Net interest | x | 8.02 | 8.36 | ||||||
| Net debt/market cap | % | 11.01% | 9.56% | ||||||
| Net debt/Equity | x | 1.73 | 1.73 | ||||||
| Gross debt/equity | x | 3.06 | 3.06 | ||||||
ETFs that hold Cencora
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Russell Mid-Cap Growth ETF | IWP | 4 | 2.01% |
| Invesco S&P 500 Revenue ETF | RWL | 10 | 1.73% |
| T. Rowe Capital Appreciation Equity ETF | TCAF | 7 | 2.45% |
| iShares MSCI Global Min Vol Factor ETF | ACWV | 9 | 1.03% |
| BMO Low Volatility US Equity ETF | ZLU.TO | 2 | 2.95% |
| JPM Global Equity Premium Income Active UCITS ETF - USD (dist) | JGPI.DE | 8 | 1.18% |
| Franklin U.S. Mid Cap Multifactor Index ETF | FLQM | 5 | 1.17% |
| VanEck Pharmaceutical ETF | PPH | 8 | 4.37% |
| John Hancock Exchange Traded Fund Trust - John Hancock Discipline Value Select ETF | JDVL | 9 | 2.83% |
| Thrivent Small-Mid Cap Equity ETF | TSME | 9 | 1.97% |
Funds with Cencora among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Russell Mid-Cap Growth ETF | IWP | 4 | 2.01% |
| Invesco S&P 500 Revenue ETF | RWL | 10 | 1.73% |
| T. Rowe Capital Appreciation Equity ETF | TCAF | 7 | 2.45% |
| iShares MSCI Global Min Vol Factor ETF | ACWV | 9 | 1.03% |
| BMO Low Volatility US Equity ETF | ZLU.TO | 2 | 2.95% |
| JPM Global Equity Premium Income Active UCITS ETF - USD (dist) | JGPI.DE | 8 | 1.18% |
| Franklin U.S. Mid Cap Multifactor Index ETF | FLQM | 5 | 1.17% |
| VanEck Pharmaceutical ETF | PPH | 8 | 4.37% |
| John Hancock Exchange Traded Fund Trust - John Hancock Discipline Value Select ETF | JDVL | 9 | 2.83% |
| Thrivent Small-Mid Cap Equity ETF | TSME | 9 | 1.97% |
Funds with Cencora among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free